Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have significantly advanced the treatment of diabetes and obesity along with their associated cardiometabolic complications since their initial approval by the U.S. Food and Drug Administration (FDA) in 2005 [1, 2]. This evidence concerns the gene GLP1R and obesity disorder.